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ABSTRACT 26 
Glioblastoma multiforme (GBM) is the most common and malignant type of primary brain tumor and is 27 
characterized by its sudden onset and invasive growth into the brain parenchyma. The invasive tumor cells 28 
evade conventional treatments and are thought to be responsible for the ubiquitous tumor regrowth. 29 
Understanding the behavior of these invasive tumor cells and their response to therapeutic agents could 30 
help improve patient outcome. In this study, we present a GBM tumorsphere migration model with high 31 
biological complexity to study migrating GBM cells in a quantitative and qualitative manner. We 32 
demonstrated that the in vitro migration model could be used to investigate both inhibition and stimulation 33 
of cell migration with oxaliplatin and GBM-derived extracellular vesicles, respectively. The intercellular 34 
heterogeneity within the GBM tumorspheres was examined by immunofluorescent staining of 35 
nestin/vimentin and GFAP, which showed nestin and vimentin being highly expressed in the periphery of 36 
tumorspheres and GFAP mostly in cells in the tumorsphere core. We further showed that this phenotypic 37 
gradient was present in vivo after implanting dissociated GBM tumorspheres, with the cells migrating away 38 
from the tumor being nestin-positive and GFAP-negative. These results indicate that GBM tumorsphere 39 
migration models, such as the one presented here, could provide a more detailed insight into GBM cell 40 
biology and prove highly relevant as a pre-clinical platform for drug screening and assessing drug response 41 
in the treatment of GBM. 42 
Keywords: glioblastoma; GBM; migration; invasion; nestin; GFAP; tumorsphere; extracellular vesicles; 43 
oxaliplatin 44 
  45 
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INTRODUCTION 46 
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with a median 47 
overall survival of only 15 months with the present standard of care [1]. Current best practice for treating 48 
these tumors consists of maximal surgical resection followed by concomitant radio- and chemotherapy, but 49 
recurrence of the tumor still remains ubiquitous [2]. GBM is characterized by its rapid growth and invasion 50 
into the surrounding brain parenchyma, high vascularization, and hypoxic niches harboring cancer stem-like 51 
cells within the tumor milieu [3]. Therefore, the complexity in the study of GBM resides in the 52 
heterogenous nature at the molecular and cellular level, which hinders the derivation of representative in 53 
vitro and in vivo GBM models. The study of GBM’s ability to invade the brain parenchyma could potentially 54 
reveal new targets for treatment by helping researchers understand the mechanisms driving cell invasion. 55 
To facilitate this understanding, in vitro migration or invasion assays are commonly used [4]. Identification 56 
of drugs or factors that can inhibit or stimulate cancer cell migration also rely on the use of in vitro studies 57 
to select promising candidates for further assessment in vivo. 58 
In vitro, invasion and migration assays are typically defined by separate parameters: Invasion 59 
assays are characterized by embedding cells in a 3D milieu where a restructuring of the extracellular matrix 60 
(ECM) takes place, whereas migration is defined by cells moving on a 2D ECM, i.e. Matrigel or collagen 61 
matrices [4]. Many migration assays today rely on the use of adherent monolayer cell cultures (2D cultures) 62 
that typically are dependent on the addition of serum to the growth medium for cell propagation [4]. In 63 
recent years, more focus has been drawn to the use of cancer cell lines that are cultured as non-adherent 64 
tumorsphere cultures without the addition of serum (3D cultures) [5]. Such cells have usually been cultured 65 
in medium favoring stem-like properties that enable the formation of tumorspheres from single cancer 66 
cells. When reaching a certain size, tumorspheres can display different cellular phenotypes generating a 67 
more complex tumor-like composition [6]. The invasive potential of cancer cells has been directly 68 
correlated to their degree of malignancy, and often the cells found to facilitate the process of tissue 69 
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invasion and metastasis have been identified as cancer cells with stem-like properties [7,8]. The 70 
extracellular matrix in the tissue harboring the tumor plays an important role in cancer cell invasion, 71 
modulating which cells move and which cellular pathways are utilized during the event [9]. This complex 72 
microenvironment can, to some extent, be mimicked in in vitro migration assays where different matrix 73 
components applied can affect the cells in different ways. For example, some studies apply a matrix 74 
constituted of only a single type of ECM protein such as collagens or fibronectin, and others apply more 75 
complex mixtures such as Matrigel [9–12].  76 
In this study, we provide a more biologically relevant model with respect to cell migration by 77 
combining primary tumorsphere cell cultures and complex ECM to create a more relevant milieu with 78 
respect to cancer cell migration. We refine an established tumorsphere migration model to include both 79 
real time quantification and the possibility to do subsequent high-resolution microscopy to assess 80 
tumorsphere characteristics. The model uses a primary GBM cell line grown on Geltrex. A characterization 81 
of intra-tumorsphere cellular heterogeneity was done by visualizing a gradient in nestin/vimentin and Glial 82 
Fibrillary Acidic Protein (GFAP) expression between the tumorsphere periphery and core. The in vitro study 83 
was supported by ex vivo examination of such phenotypic gradient in an orthotopic mouse GBM xenograft 84 
generated with the same GBM tumorspheres. To illustrate that this model can be used to both inhibit and 85 
stimulate GBM cell migration, we used oxaliplatin and extracellular vesicles (EVs) derived from GBM cells, 86 
respectively, hereby underscoring its potential as an assay of therapeutic efficacy. 87 
 88 
MATERIALS AND METHODS 89 
Ethical approval 90 
All experimental procedures were approved by the Danish Animal Welfare Council, the Danish Ministry of 91 
Justice (license no. 2019-15-0201-00920). NMRI nude mice (Taconic Biosciences, Denmark) were housed in 92 
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IVC rack in Type III SPF cages with a maximum of 8 mice in each cage. Food and water were available ad 93 
libitum. 94 
Cell culture 95 
Primary GBM tumorsphere cultures T78 were generated as previously described and cultured in 96 
Neurobasal A medium supplemented with 1 % B27 supplement, 2 mM L-glutamine and 20 ng/mL EGF and 97 
bFGF and penicillin-streptomycin (100 U/mL penicillin and 100 µg/mL streptomycin) [13,14]. T78 cells were 98 
used at passages 18-20 throughout all experiments. For EV isolation, a secondary GBM cell line was 99 
cultured in DMEM-F12 supplemented with 10 % EV-depleted FCS and penicillin-streptomycin (100 U/mL 100 
penicillin and 100 µg/mL streptomycin). EV-depleted FCS was generated by ultracentrifugation of FCS at 101 
120,000 RCF for 16 hours, where the supernatant was further used for culturing cells for EV production.  102 
Geltrex coating 103 
Geltrex (ThermoFisher, MA, USA; #A1413302) was thawed on ice at 4°C prior to use. After thawing, Geltrex 104 
matrix was diluted 1:50 in growth medium and seeded in a volume of 700 µL per well into the middle eight 105 
wells of a 24 well plate. Everything was kept cool on ice while resuspending and coating the wells. The 106 
plates were then incubated at 37°C for minimum 4 hours to let the Geltrex matrix solidify. 107 
Isolation of single tumorspheres and treatment 108 
Prior to GBM tumorsphere isolation, the plates were cooled to room temperature (usually 10-20 min), and 109 
the medium was then removed from the wells. Tumorspheres were selected according to their size 110 
(approximately 100-200 µm in diameter) and isolated with a pipette in a volume of 0.5 µL under a phase-111 
contrast microscope. One tumorsphere was spotted into the middle of each well. The surrounding wells 112 
were filled with 500 µL mL PBS to avoid evaporation and drying of the tumorspheres. After spotting the 113 
tumorspheres, the plates were incubated at 37°C for 30-45 min to allow adherence to the gel, and then 700 114 
µL of pre-heated growth medium was carefully added to each tumorsphere-containing well.  115 
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The day after spotting the tumorspheres (referred to as day 1 or D1), treatment groups were randomly 116 
assigned. Tumorspheres received a single-dose of oxaliplatin on day 1 at a concentration of 5 µM, similar to 117 
the concentration used in other studies [15]. EVs were added in a concentration of approximately 6.5 x 107 118 
particles per well in triplicates. EVs isolated from non-conditioned medium were included in triplicates as a 119 
control to account for the potential effects of EVs or other factors remaining in the medium. No treatment 120 
controls (NTC) were done in five replicates. TGF-β1 was added to the cells in a concentration of 4 ng/mL in 121 
triplicates. 122 
Quantitative data acquisition and analysis 123 
Phase-contrast images were acquired each day for a total of 5 days (D0 – D4) with a Zeiss Axio Observer Z.1 124 
(DE). Area of the growing spheres was estimated with Zeiss ZEN2 Blue Edition. All graphs were generated in 125 
GraphPad Prism 6. 126 
Fluorescence microscopy and time-lapse imaging on tumorspheres in vitro 127 
Sterile coverslips were placed in each well, and Geltrex coating was done as previously described. Bulk GBM 128 
tumorspheres were seeded (10-30 per well) in growth medium and incubated overnight. Tumorspheres 129 
were washed in PBS and fixed in 4 % formaldehyde for 15 min. at room temperature. Tumorspheres were 130 
then washed again and blocked in 5 % BSA PBS for 30 min. Primary antibodies Ms anti-human nestin 131 
(Abcam, Cambridge, UK; #ab22035; 1:1000), Ms anti-vimentin (Abcam; #ab92547; 1:1000), Rb anti-GFAP 132 
(Dako, DK; #Z0334; 1:1000), were added to cells in 0.5 % BSA PBS and incubated on a rocking table 133 
overnight at 4°C. Tumorspheres were then washed and secondary antibodies Dnk-anti-Ms-Alexa-488 134 
(ThermoFisher; #R37114; 1:1000), Dnk-anti-Rb-Alexa-555, (ThermoFisher; #A-31572; 1:1000) were added 135 
to cells and incubated on a rocking table for 2 hours at room temperature. Tumorspheres where then 136 
washed and stained with Hoechst33342 (ThermoFisher; #H3570; 1:3000) for 10 min on a rocking table at 137 
room temperature. Coverslips were transferred to SuperFrost (Menzel Gläser, ThermoFisher) slides with a 138 
drop of fluorescent mounting medium (Dako; #S3023) and stored in a fridge at 4 – 6°C overnight to harden. 139 
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Images were obtained on Zeiss Observer Z.1 with Apotome-2 structured illumination microscopy with a 40x 140 
NA1.30 objective (Zeiss). Quantification of GFAP:nestin ratio between core and periphery was done by 141 
threshold analyses of 4 images and presented as a bar chart with mean + SD in GraphPad Prism 6. Time-142 
lapse imaging was done on tumorspheres directly after seeding onto Geltrex and imaged on a Zeiss 143 
Observer Z.1 with a mounted Pecon Incubator P S compact (Pecon, Erbach, DE). Images were acquired with 144 
Zeiss ZEN2 Blue software every 10 min. with automated focus over the course of 24 hours. Images and 145 
time-lapse series were processed and analyzed in Fiji [16].  146 
Paraffin embedding and immunostaining of free-floating GBM tumorspheres in vitro 147 
Tumorspheres were fixed free-floating in methanol for five minutes before embedding in paraffin for 148 
sectioning. 5 µm sections of embedded spheroids were cut on a Leica RM 2255 microtome (Nussloch, DE) 149 
and fixated on glass slides by melting of paraffin residue at 60°C for one hour. Sections were stained using 150 
primary antibodies Rb anti-GFAP (Dako; #Z0334; 1:200) and Ms anti-human nestin (Abcam; #ab22035; 151 
1:200). Secondary antibodies were Dnk-anti-Ms-Alexa-488 (Invitrogen; #A-21202; 1:500) and Gt-anti-Rb-152 
Alexa-594 (Invitrogen, CA, USA; #A-11037; 1:500). Antigen retrieval was performed using a 10 mM sodium 153 
citrate buffer (pH 6.0) with 0.05% Tween. Cells were additionally immunostained with 4,6-diamidino-2-154 
phenylindole (DAPI) (Sigma; #000000010236276001; 1:500) for nuclear staining. Slides were mounted using 155 
fluorescent mounting medium (Dako; #S3023) and images were acquired on a Zeiss Observer Z.1 using the 156 
Colibri light source (Zeiss) and Orca-Flash4.0 V2 (Hamamatsu) as the detector. To quantify the area that 157 
nestin and GFAP signal covers, the manual threshold tool in Fiji was used. Five images of five different 158 
tumorspheres were used for thresholding and the area coverage in percent was normalized for each 159 
tumorsphere to the respective tumorsphere size determined by area of the nuclear stain (DAPI) when over-160 
saturated. Data was plotted and analyzed in GraphPad Prism 6. 161 
GBM mouse xenograft model 162 
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T78 GBM tumorspheres were grown until 100-200 µm in diameter and dissociated with TrypLE 163 
(ThermoFisher; #12604013). Cells were then washed twice, counted, and cell numbers adjusted to 20.000 164 
cells/µL. A total of 10 µL (200.000 cells) was resuspended in growth medium and injected into the striatum 165 
(0.5 mm below Bregma, 1.5 mm lateral) of nude NMRI mice using a syringe pump running at 30 nL/s. To 166 
avoid cells being dragged back up with the removal of the needle, the needle was left in the injection site 167 
for 3 minutes prior to removal. Tumor size and growth was monitored with MRI (BioSpec 7T, Bruker, 168 
Mannheim, DE) using T2-weighted sequence of the mouse brain obtained in axial and coronal directions 169 
(Figure S1). Mice were anesthetized with Sevoflurane when the tumor size reached 10 – 20 mm3 and 170 
transcardially perfused with PBS followed by perfusion of 4 % methanol-free paraformaldehyde. Brains 171 
were removed from the skull and post-fixed overnight at 4°C. 172 
Fluorescence immunohistochemistry on GBM tumors 173 
Brains were immersed in cryoprotection with 10%, 20% and 30% sucrose (each step overnight), embedded 174 
in OCT (Micro and Nano; #16-004004) and frozen in isopentane on dry ice. 30 μm coronal sections were 175 
obtained with a cryostat (Leica CM 1850 UV). Sections were blocked with blocking solution containing 5 % 176 
donkey serum (Millipore, Darmstadt, DE; #S30-100ML) and 0.2 % saponin (VWR, DK; #27534.187) in TBS for 177 
1 hour. The sections were then blocked with mouse on mouse blocking reagent (Vector Laboratories, CA, 178 
USA; Cat. #MKB-2213) and after 2 hours, the solution was changed to mouse on mouse blocking reagent in 179 
0.2 % saponin in TBS for 1.5 hours. The sections were incubated with primary antibodies: Rb anti-human 180 
GFAP (Abcam; #ab33922; 1:500) and Ms anti-human nestin (Abcam; #ab22035; 1:400) overnight at 4°C. 181 
After washing in TBS, sections were stained with Hoechst 33342 (ThermoFisher; #62249; 1:1000) and 182 
secondary antibodies: Dnk-anti-Rb-Alexa-568 (Invitrogen; Cat. #A10042; 1:1000) Dnk-anti-Ms-Alexa-647 183 
(Invitrogen; Cat. #A-31571; 1:1000) for 3 hours at room temperature. Sections were washed and mounted 184 
using ProLong™ Diamond Antifade Mountant mounting media (Invitrogen; #P36970). Samples were imaged 185 
with a confocal laser scanning microscope (Zeiss LSM 710) and fluorescence slide scanner (Zeiss Axio 186 
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Scan.Z1). For the images obtained with fluorescent slide scanning shading correction was applied using 187 
Zeiss ZEN Blue 2.3 software. Secondary antibody controls are presented in Figure S2. 188 
EV isolation 189 
EVs were isolated from GBM cells grown in DMEM-F12 supplemented with 10 % FCS and 1 % penicillin-190 
streptomycin. To produce conditioned medium (CM), EV-depleted FCS was made by ultracentrifugation of 191 
FCS at 120,000 RCF for > 16 hours. The EV-depleted FCS was then diluted to 10 % in DMEM-F12 and added 192 
to the cells in T175 flasks (30 mL) and incubated for 24 hours at 37°C. CM was harvested and centrifuged 193 
for 20 min at 2000 RCF and either stored at -20°C until further processing (for maximum two weeks) or 194 
processed directly. The supernatant was transferred to a new tube and centrifuged at 9000 RCF for 30 min. 195 
The supernatant was filtered through 0.2 µm filters and centrifuged at 120,000 RCF for 2.5 hours. The 196 
resulting supernatant was discarded, and the pellet resuspended in growth medium or Trehalose-PBS, for 197 
either Tumorsphere migration assay or NTA and TEM validation (see below), respectively. The EV CTRL was 198 
made by running non-conditioned medium through the exact same EV isolation protocol. 199 
Nanoparticle Tracking Analysis 200 
All NTA analyses were done on a NanoSight LM-10 (Malvern, UK). A dilution of the EVs was made to include 201 
around 50 – 100 particles at once in the field of view. For video recording, shutter was between 700 and 202 
800, gain was between 550 and 620, and the capture time for each recording was 30 s. For each sample, a 203 
total of five videos were recorded. Prior to NTA, screen gain was adjusted to 2, blur was set to 3x3, and 204 
detection threshold set between 16 and 28. Tracks were exported to Microsoft Excel and imported into 205 
GraphPad Prism 6 (GraphPad, CA, USA) for further analysis. 206 
Immunoelectron microscopy of immunogold-labelled EVs 207 
Immunolabelling was performed by mounting 5 uL concentrated samples on carbon- coated, glow 208 
discharged 400 mesh Ni grids for 30 s and washed 3 times with PBS. Grids were blocked with 0.5% 209 
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ovalbumin in PBS and then incubated with a cocktail of primary anti-CD9 (Ancell, MN, USA; #SN4/C3-3A2; 210 
1:50), anti-CD63 (Ancell; #AHN16.1/46-4-5; 1:50) and anti-CD81 (Ancell; #1.3.3.22; 1:50) monoclonal 211 
antibodies in 0.5% ovalbumin in PBS for 30 min at 37°C. After incubation grids were washed 3 times with 212 
PBS and incubated with secondary antibody goat anti-mouse conjugated with 10 nm colloidal gold (British 213 
BioCell, Cardiff, UK) 1:25 in 0.5% ovalbumin in PBS for 30 min at 37°C. The grids were then washed with 3 214 
drops of PBS, before incubation on 3 drops of 1% cold fish gelatin for 10 min each. The grids were finally 215 
washed with 3 drops of PBS before staining with 1 drop of 1% (w/v) phosphotungstic acid at pH 7.0 and 216 
blotted dry. Images were obtained with a transmission electron microscope (JEM-1010, JEOL, Eching, 217 
Germany) operated at 60 keV coupled to an electron- sensitive CCD camera (KeenView, Olympus, Center 218 
Valley, PA, USA). For size determination of visible EVs a grid-size replica (2,160 lines/mm) was used. See 219 
Table S1 for full antibody list.  220 
Production of oxaliplatin-loaded stealth liposomes 221 
Stealth liposomes were produced from a lipid formulation containing hydrogenated soybean 222 
phosphatidylcholine (HSPC), DSPE-PEG2000, and cholesterol (Lipoid GmbH, Ludwigshafen, DE) in a molar 223 
ratio of 56.8:38.2:5 mol%. Hydration of the lipid powder was done for 1 hour at 65°C 10 mM HEPES and 5 % 224 
glucose (pH 7.4) containing oxaliplatin (Lianyungang Guiyuan Chempharm Co., LTD, Jiangsu, PRC). Extrusion 225 
of the liposomes and determination of phospholipid and oxaliplatin concentration were performed as 226 
described in Johnsen et al. (2019) [17]. The hydrodynamic diameter and ζ-potential of the resulting 227 
oxaliplatin-loaded stealth liposomes were measured with a Zetasizer (ZetaPALS, Brookhaven Instruments 228 
Ltd., NY, USA), showing a diameter of approximately 120 nm and a net negative surface charge. 229 
RESULTS 230 
Intra-tumorsphere cellular heterogeneity display in vitro 231 
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Since GBM tumorspheres grow in a non-adherent 3D fashion, we hypothesized that a cellular heterogeneity 232 
could arise within each tumorsphere. First, time-lapse image series were acquired of tumorspheres to 233 
visualize attachment to Geltrex and migration for the first 24 hours (see Supplementary Video 1). The time-234 
lapse gave us an idea of how the tumorspheres transition from a free-floating state to becoming attached 235 
to the Geltrex (illustrated in Figure S3A). To examine the intercellular heterogeneity within the 236 
tumorspheres, tumorspheres were seeded in wells containing a Geltrex-coated coverslips and incubated 237 
those overnight for subsequent immunostaining and high-resolution fluorescence microscopy. In the first 238 
instance, smaller tumorspheres were stained for nestin expression to allow for high-resolution imaging of 239 
whole tumorspheres. On visual inspection, the lower slices of the microscopy Z-stack, showed that the 240 
tumorsphere core was nestin-negative, contrary to the positive nestin staining in the periphery (Figure 241 
S3B). This pattern of nestin expression in the cells prompted us to look for more differentiated cells in the 242 
tumorspheres. This was done by co-staining for GFAP and nestin/vimentin. Nestin and vimentin are known 243 
to associate with invasive cancer cells and cancer stem-like cells in GBM, whereas GFAP expression was 244 
indicative of a less invasive phenotype and is expressed in opposition to nestin, perhaps allowing for a 245 
phenotypical distinction [18–21]. Images obtained in the periphery of tumorspheres showed cells highly 246 
positive for vimentin and nestin and less positive for GFAP (Figure 1A, Figure S4). Interestingly, long 247 
projections were shown to stretch from the core of tumorspheres towards the periphery, possibly 248 
resembling astrocytic end-feet or tumor microtubes [22].  249 
***INSERT FIGURE 1*** 250 
To further illustrate the phenotypical gradient from the core to the periphery, images were taken close to 251 
the core with an overlapping image towards the periphery. Here, less nestin-positive and more GFAP-252 
positive cells were observed by the core (Figure 1B), whereas the peripheral cells were all nestin and GFAP-253 
positive. However, despite being present, the GFAP displayed a fragmented (or non-filamentous) structure 254 
in the periphery, which might indicate an ongoing degradation of GFAP at the time of acquisition (less than 255 
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24 hours after seeding the tumorspheres) (Figure 1C, Figure S5). Close to the core, GFAP expression was 256 
predominantly displayed as filamentous structures (Figure 1B-C, Figure S5). Orthogonal views showed a 257 
double-layer of cells close to the core with the top cell-layer mainly being nestin-positive/GFAP-negative 258 
and the bottom layer mainly nestin-negative/GFAP-positive. In the tumorsphere periphery, orthogonal 259 
views confirm these observations of fragmented GFAP expression, which also appeared to localize inside 260 
the nucleus (Figure 1C, Figure S5). Quantification of the GFAP and nestin expression revealed significant 261 
differences in the GFAP-to-nestin ratios when comparing the core and peripheral regions of the 262 
tumorspheres (Figure 1D).  This underscored the observation that GFAP expression is decreased with the 263 
increase in migratory capacity of the tumorsphere cells. 264 
To examine whether a heterogenous expression of GFAP/nestin was also evident in whole non-adherent 265 
tumorspheres (free-floating), we fixed and paraffin-embedded whole tumorspheres and cut them in 4 µm 266 
sections for immunofluorescence staining (Figure 2A). Most cells in the tumorspheres were nestin-positive 267 
with the nestin staining covering 66 % of the tumorspheres, and only 10 % appearing to be GFAP-positive 268 
(Figure 2B). The GFAP pattern appeared quite diffuse, but the cells in the outermost periphery were GFAP-269 
negative and nestin-positive, confirming the heterogenous gradient shown in the Geltrex setup.  270 
***INSERT FIGURE 2*** 271 
Tumorsphere phenotypic gradient is reflected in vivo 272 
Given the observations and phenotypic distinctions in the in vitro tumorsphere migration model, an in vivo 273 
experiment was set up using the same GBM tumorsphere culture to see if the in vitro model recapitulated 274 
the situation observed in vivo. Dissociated T78 GBM tumorspheres were stereotactically implanted into the 275 
striatum of nude mice and tumor growth monitored weekly with MRI (Figure S1). When the tumor reached 276 
a sufficient size (10 – 20 mm3), mice were sacrificed and whole brains were removed and stained for human 277 
GFAP and human nestin (Figure 3). Fluorescence slide scans of whole brain slices were correlated to the last 278 
MRI sequence obtained just before the mice were sacrificed and showed that fluorescence imaging was 279 
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done approximately in the center of the tumor (Figure 3A-B, Figure S1C). Confocal microscopy of the same 280 
slides showed that the tumor core contained both nestin and GFAP-positive cells, and the tumor periphery 281 
showed a change towards nestin-positive and GFAP-negative cells with increased distance from the tumor 282 
core (Figure 3C-D). In the area between the more distant tumor cells and the tumor core, tumor cells 283 
positive for both nestin and GFAP were observed (Figure 3D). This could both indicate a transition zone 284 
towards a more nestin-positive phenotype or that the cells expressing both intermediate filaments possess 285 
migratory potential. The most distant tumor cells identified had migrated to the frontal superficial 286 
hippocampal formation and were nestin-positive and GFAP-negative (Figure 3E). 287 
***INSERT FIGURE 3*** 288 
Oxaliplatin reduces primary GBM tumorsphere migration in vitro 289 
After having established that the intratumoral heterogeneity was recapitulated in our in vitro model, we 290 
next wanted to study the potential of using the model as an assay of therapeutic efficacy. For this purpose, 291 
we utilized the platinum-based chemotherapeutic drug, oxaliplatin [23]. Single GBM tumorspheres were 292 
seeded onto Geltrex matrix on day 0, and treatment groups were assigned on day 1, followed by the 293 
addition of 5 µM oxaliplatin. Phase-contrast images were acquired daily and the area of migration was 294 
measured (Figure 4A). On day 1, total area between groups was similar, however, a large reduction in 295 
migration was observed the following days after oxaliplatin treatment compared to controls (Figure 4B). 296 
During the experiment, the tumorspheres in the control group increased five-fold in size whereas the 297 
tumorspheres that received oxaliplatin increased only two-fold in size (Figure 4C). This indicated that the 298 
treatment had reduced the growth more than two-fold compared to that of the control after a single dose 299 
of oxaliplatin. When encapsulating oxaliplatin into stealth liposomes with low capacity for associating and 300 
endocytosing into the cells due to their polymer surface coating, the effects of oxaliplatin were markedly 301 
reduced (Figure 4C). Thus, the growth-inhibiting effects of oxaliplatin were successfully modelled and could 302 
be diminished by interfering with the interaction potential between the drug and GBM cells. 303 
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***INSERT FIGURE 4*** 304 
GBM-derived EVs stimulate GBM tumorsphere growth in vitro 305 
To illustrate that the Geltrex migration model can also be used to evaluate potential stimulatory effects on 306 
GBM cell migration, EVs isolated from a GBM-derived secondary cell line were applied to the system. The 307 
EVs were characterized by NTA and immunogold TEM, and subsequently added to the tumorspheres on day 308 
1. The administrated EVs ranged in size from ~50 – 350 nm with most of the EVs being around 150 nm 309 
(Figure 5A). NTA measurements on EV CTRL (EVs isolated from non-conditioned medium) did not yield 310 
enough events for analysis, thus were regarded as being EV-depleted. The tetraspanin proteins CD9, CD63 311 
and CD81 are among the most widely used EV markers, and to validate that the isolated EVs used in this 312 
study were in fact EVs, we performed immunogold staining with a cocktail of monoclonal antibodies against 313 
these three types of tetraspanins followed by morphological assessment using TEM. The antibody-gold 314 
nanoparticle complexes showed an association to the outer membrane of the particles, indicating that the 315 
particles were positive for one or more of the tetraspanins and thus confirming that they were EVs (Figure 316 
5B, Figure S6). The tumorspheres that received GBM EVs showed a significant increase in area compared to 317 
all the controls (Figure 5C-D). The GBM EVs increased GBM cell migration by more than 30 % compared to 318 
both NTC and EV CTRL (EVs isolated from non-conditioned medium). TGF-β1 was included as a simple 319 
positive control but did not enhance the migration of the cells in our setup. These results indicate that EVs 320 
isolated from a secondary GBM cell line could significantly stimulate GBM tumorsphere migration in vitro. 321 
Thus, it was demonstrated that both stimulatory and inhibitory effects on GBM cell migration could be 322 
measured using this model.  323 
***INSERT FIGURE 5*** 324 
DISCUSSION 325 
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The highly invasive behavior of GBM limits therapeutic efficacy of current treatment strategies, which is 326 
substantiated by the almost ubiquitous occurrence of relapse [24]. Only subtle progress in patient 327 
prognosis has been made during the past two decades with a two-month increase in median survival by the 328 
addition of temozolomide to the treatment regimen [25]. The cells that most frequently invade the 329 
surrounding brain parenchyma and migrate far away from the tumor core (or primary tumor) have been 330 
shown to possess stem-like properties [26–28]. Understanding the invading and migrating GBM cells 331 
potentially harbors an avenue for improving treatment and therefore patient prognosis. Here, we 332 
presented a quantitative migration model based on GBM tumorspheres for assessment of cancer inhibiting 333 
or stimulating substances.  334 
 Generally, the study of GBM invasion and migration dynamics and the effects of different 335 
treatments on this property in vitro is limited by the model cell line and the assay of choice. Many different 336 
quantitative cell invasion and migration assays exist, including the wound-healing assay, transwell assay, 337 
cell exclusion assay, and fence (or ring) assay [4]. One feature is common for these assays; the cells are 338 
often conveniently grown as an adherent cell monolayer, typically with the addition of serum to the culture 339 
medium. Tumorspheres on the other hand are grown in absence of serum and preferentially in stem cell-340 
promoting medium, which can induce and maintain a cellular heterogeneity within tumorspheres [29]. 341 
Tumorspheres can be generated from established cell cultures that are usually grown as a monolayer after 342 
a period of weaning or from primary cell lines directly isolated from tumor tissue [30,31]. The drawback of 343 
using monolayer cells in such an assay is that the cells might already have gone through a harsh selection 344 
process immediately after isolation, i.e. the selection of mesenchymal-like cells based on adherence, and 345 
might therefore not represent intercellular heterogeneity as well as tumorspheres from primary cells would 346 
do [29]. For example, drug resistance is different in cells grown either in 2D or 3D cultures, where the 3D-347 
cultured cells appeared to be more resistant in the study by Imamura et al. [30]. Here, they used adherent 348 
cells as a 2D culture and induced non-adherent tumorspheres from the same cells to produce a 3D culture, 349 
which indicates that the 3D organization of the cells could play a role in drug response [30]. In this study, 350 
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we presented a GBM tumorsphere migration model using primary GBM cells isolated under tumorsphere-351 
inducing conditions. We used the Matrigel-derived ECM Geltrex as the migration matrix of choice due to its 352 
complex composition, the fact that it is hESC-qualified and has a reduced concentration of growth factors. 353 
The cellular heterogeneity in our tumorsphere model showed a crude differential phenotypic 354 
gradient of cells based on their location in the tumorsphere. Nestin and vimentin were found to be highly 355 
expressed in the tumorsphere periphery, whereas GFAP was expressed both in the core and periphery. 356 
However, the structure of GFAP in the periphery appeared fragmented, which could indicate an ongoing 357 
degradation of GFAP and hence a cellular phenotype shift from GFAP-positive towards nestin/vimentin-358 
positive [32]. This reduction in GFAP expression was also reflected, when quantitatively comparing the core 359 
and peripheral regions of the tumor. We further showed a similar distribution of nestin/GFAP staining in 360 
free-floating tumorspheres in vitro and in vivo in a mouse intracranial xenograft setup using the same 361 
primary GBM cells. Nestin has for a couple of decades been known as a multi-lineage progenitor marker 362 
and was in embryonic stem cells shown to be expressed in the progenitor ‘transition’ period and then 363 
turned off when cells fully differentiated [33,34]. Similarly, glial progenitor cells were nestin-positive and 364 
GFAP-negative, but at the end of cellular differentiation, GFAP had replaced nestin [35]. Nestin has further 365 
been associated with a migratory phenotype, where it facilitates migration of neural stem cells and directs 366 
inflammatory cell migration in atherosclerosis [36,37]. In cancer, nestin expression is generally associated 367 
with cancer stem-like cells, and  more specifically in GBM, nestin has been shown to be useful for 368 
identifying migrating tumor cells [38,39]. Downregulation of nestin demonstrated a reduction of 369 
tumorsphere formation and tumor size in vivo, and overexpression results in increased cell growth, 370 
tumorsphere formation and cell invasion [40]. However, the opposite has also been reported, where 371 
downregulation of nestin increased matrix degradation and pFAK localization to focal adhesions for 372 
increased prostate cancer cell invasion, which could indicate functional differences between different types 373 
of cancer [41]. In the case of human GBM tumors, nestin is expressed in the tumor periphery and in the 374 
invading tumor cells [42]. Munthe et al. reported nestin-positive cells both in the core and periphery of 375 
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human GBM tumors, and showed that the same distribution could be seen in a GBM xenograft model, 376 
using the same cells (T78) as in our study [27,28]. This could indicate that our in vitro tumorsphere 377 
migration model shows a crude similarity to human GBM tumors, thus demonstrating a biological relevance 378 
for our tumorsphere model in drug screening and cellular responses to the drugs used. 379 
 We demonstrated that oxaliplatin could reduce tumorsphere migration by more than two-380 
fold, and by encapsulating oxaliplatin in stealth liposome these therapeutic effects were reduced. The cell 381 
repulsion effects of stealth liposome formulations can thus be reliably assessed in this model even after a 382 
period of four days as shown here, which could indicate that this migration model could provide a useful 383 
tool for researchers working on various drug delivery systems [43]. The model could also be used to 384 
visualize stimulation of GBM tumorsphere migration by adding EVs harvested from a GBM cancer cell line. 385 
The EV field is rapidly expanding with thousands of new publications each year ranging from basic biology 386 
to drug delivery. Models, such as the one presented here, could potentially contribute to elucidating 387 
functional effects of both engineered EVs for drug delivery and specific biological populations of EVs, since 388 
several studies have shown that parts of the functional cell-cell communication in GBM happens via EVs 389 
[44–47]. In addition to the quantitative assessment of EVs, the EVs secreted from the cells in such a setup 390 
can be isolated and analyzed with a potential minimum of serum-derived contaminants as they are grown 391 
under serum-free conditions, which might help with overcoming a technical barrier in EV analyses [48]. 392 
 393 
METHODOLOGICAL CONSIDERATIONS 394 
Although we do not directly demonstrate a high-throughput model, a few protocol alterations could easily 395 
make it high-throughput for GBM drug screening. We used 24-well plates and manually picked single 396 
tumorspheres and seeded into the wells, but this process could be replaced by a limiting dilution of 397 
tumorspheres into 96-well plates. We manually acquired images of the tumorspheres and this could be 398 
optimized by acquiring an automated image station such as IncuCyte (Essen Bioscience) or Celigo 399 
(Nexcelom Bioscience). Vinci et al. demonstrated a high-throughput 3D GBM tumorsphere invasion assay 400 
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using such an image station with automated quantitation of invasion [49]. To further enhance cellular 401 
complexity of our model, GBM organoids could be used. Development in the field of organoid research is 402 
accelerating and several techniques and models within the GBM field are emerging, showing much more 403 
cellular complexity than tumorspheres [50,51]. However, generation of organoids takes longer time (up to 404 
several months) and thus serves as rate-limiting for the use in high-throughput drug screens [50]. In 405 
between the convenience of monolayer cultures and the lengthy process of organoid generation, 406 
tumorspheres might present an acceptable middle ground with both convenient culturing and sufficient 407 
complexity. 408 
 409 
CONCLUSIONS 410 
In conclusion, we presented a GBM tumorsphere migration model with intercellular heterogeneity, which 411 
might provide a relevant in vitro model for drug response evaluation. The cellular organization and 412 
complexity of cancers are hard to reproduce in vitro for high-throughput drug screening and drug response 413 
evaluation, but we believe that tumorsphere migration models such as presented here could be an 414 
important step towards more accurate drug screening prior to evaluation in expensive pre-clinical animal 415 
models. The research in this field is fortunately accelerating with more advanced cell models and 416 
equipment for better analysis. 417 
 418 
419 
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FIGURE LEGENDS 554 
Figure 1: Intra-tumorsphere cellular heterogeneity. (A) Immunofluorescence stainings for nestin or 555 
Vimentin (green) and GFAP (red). Images show nestin and Vimentin expression most prominent in the 556 
tumorsphere periphery and GFAP expression mostly from the tumorsphere core with GFAP-positive 557 
filaments stretching from core to periphery (arrows). Scale bars: 20 µm. (B) Overlapping 558 
immunofluorescence images acquired to visualize differences in nestin/GFAP expression based on cellular 559 
location. The periphery shows filamentous nestin distribution and non-filamentous (or fragmented) GFAP 560 
distribution, which was also seen within the nucleus. Closer to the core, where a double cell layer was 561 
observed, the bottom cells appeared GFAP-positive/nestin-negative and the top cells appeared nestin-562 
positive/GFAP-negative. Yellow stippled line approximately indicates the transition zone. Arrows indicate 563 
examples of filmentous GFAP. Scale bars: 20 µm. (C) Zooms on orthogonal regions from both periphery and 564 
core, which shows fragmented and intra-nuclear GFAP localization in the periphery and filamentous 565 
cytosolic GFAP in the core. In the periphery, arrows indicate fragmented GFAP inside nuclei and in the core, 566 
arrows show nuclei free of GFAP. (D) Quantification of GFAP:Nestin ratio between tumorsphere core and 567 
periphery. Data is presented as Mean + SD from four separate images. 568 
Figure 2: Nestin/GFAP distribution in free-floating tumorspheres. (A) Immunofluorescence of nestin (green) 569 
and GFAP (red) showed most of the cells being nestin-positive and fewer cells GFAP-positive. Scale bar: 50 570 
µm (B) Estimation of area coverage for each signal in percent using threshold analysis. Total nestin 571 
coverage was around 66 % and GFAP total coverage around 10 %. 572 
Figure 3: Distribution of nestin/GFAP in a GBM mouse xenograft model using the same cells. (A) 573 
Fluorescence slide scanning of whole brain slices stained with GFAP (green) and nestin (red). Image show 574 
both nestin and GFAP expression in the tumor core, but peripheral cells appear only nestin-positive (see 575 
asterix). Scale bar: 1 mm. (B) MRI of mouse brain showing the tumor just prior to sacrificing the mouse. 576 
Image shows that the fluorescent stainings were done on sections from the middle of the tumor (more 577 
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details in Figure S1C). (C) Fluorescence laser-scanning confocal image of from the tumor core showing both 578 
nestin and GFAP-positive cells. Scale bar: 50 µm. (D) Fluorescence laser-scanning confocal image of the 579 
tumor periphery showing the tumor cells farthest from the tumor being nestin-positive and GFAP-negative. 580 
Scale bar: 50 µm. (E) Fluorescence slide scan zoom-in on frontal superior hippocampal formation showing 581 
nestin-positive/GFAP-negative tumor cells. Scale bar: 200 µm. 582 
Figure 4: Inhibition of tumorsphere migration with Oxaliplatin. (A) Daily phase-contrast images of 583 
representative tumorspheres from each group visualizing the difference in area of migration after 584 
treatment initiated on D1. Scale bar: 400 µm. (B) Bar chart of total tumorsphere area measured on each 585 
day. (C) Tumorsphere migration normalized by applying a fold-change from each day after treatment (D2-586 
D4) to the day of treatment (D1). Normalized data is presented as mean ± SEM. P = 0.03 – 0.05 on D3-D1, P 587 
= 0.002 on D4-D1. 588 
Figure 5: Stimulation of tumorsphere migration with GBM-derived extracellular vesicles. (A) Size 589 
distribution of EVs measured with NTA. (B) characterization of EVs by immunogold TEM using a cocktail of 590 
antibodies against the tetraspanins CD9, CD63 and CD81. Scale bar: 100 nm. (C) Bar chart of total 591 
tumorsphere area measured on each day.  (D) Tumorsphere migration normalized by applying a fold-592 
change from each day after treatment (D2-D4) to the day of treatment (D1). EV CTRL consisted of EVs 593 
isolated from non-conditioned medium and TGF-β1 was included as a positive migration control, however, 594 
it did not induce any significant effects. Normalized data is presented as mean ± SEM. P = 0.002 – 0.02 on 595 
D3-D1, P = 0.002 – 0.02 on D4-D1. 596 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
HIGHLIGHTS 
• Intratumoral heterogeneity is present in complex primary GBM tumorspheres in vitro 
• Heterogeneity is visualized as a function of migration by differential distribution of nestin/vimentin 
and GFAP between core and periphery in vitro and in vivo 
• Patient-derived GBM tumorspheres are promising for use in drug screens and studies of GBM 
biology in vitro and in vivo 
 
